Batiraxcept is under clinical development by Aravive and currently in Phase I for Breast Cancer. According to GlobalData, Phase I drugs for Breast Cancer have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Batiraxcept’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Batiraxcept overview

AVB-500 is under development for the treatment of acute myelogenous leukaemia (AML), metastatic urothelial cancer including renal pelvis cancer, ureter cancer, urinary bladder cancer, urethral cancer, uterine cancer and solid tumors including platinum-resistant recurrent epithelial ovarian cancer, fallopian cancer, peritoneal cancer, pancreatic cancer, renal cancer, lung cancer, breast cancer, Zika virus infections, kidney fibrosis (IgA nephropathy), clear cell renal cell carcinoma (ccRCC), and an undisclosed cancer indication (3rd oncology), non-small cell lung cancer. The drug candidate is administered through intravenous route. The drug candidate is a fusion protein which acts by targeting growth arrest-specific protein 6 (GAS6).

Aravive overview

Aravive, formerly Versartis, is a biopharmaceutical company that develops, manufactures and commercializes medicines for the treatment of life-threatening diseases. The company’s lead product candidate include batiraxcept (AVB-500), binds to GAS6 and prevents AXL signaling to inhibit metastasis, tumor growth and restore sensitivity to anti-cancer agents. Its product treats ovarian cancer, clear cell renal cancer, pancreatic adenocarcinoma, and fibrosis. The company partners with WuXi Biologics Limited and 3D Medicines Inc., in China, Taiwan, Hong Kong and Macau to prevent human oncological diseases. Aravive is headquartered in Houston, Texas, the US.

For a complete picture of Batiraxcept’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.